Anti-metalloprotease antibody for diagnosis and treatment of cancers
US10023653B2 · kind B2 · utility
0Cited by
1References
5Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Feb 4, 2015 |
| Grant date | Jul 17, 2018 |
| Priority date | — |
| Expiry date | Feb 4, 2035 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/96486
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
Expression of proteolytically active, high molecular weight ADAM protease is relatively increased in tumor cells that also express the putative tumor stem cell marker CD133. An antibody or antibody fragment such as 8C7 monoclonal antibody may be used to selectively bind to proteolytically active, high molecular weight ADAM10 protease to thereby detect tumor cells and also as a therapeutic agent for treating cancers, tumors and other malignancies inclusive of leukemia, lymphoma, lung cancer, colon cancer, adenoma, neuroblastoma, brain tumor, renal tumor, prostate cancer, sarcoma and/or melanoma.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.